Evidence map›Paper›PMID 39106449›Full record

ArticleCancer research2024

A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms.

Fresia Pareja, Higinio Dopeso, Yi Kan Wang, Andrea M Gazzo, David N Brown, Monami Banerjee, Pier Selenica, Jan H Bernhard, Fatemeh Derakhshan, Edaise M da Silva and 29 more

Abstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Pitfalls in the Histological Diagnosis of Morphologic Variants of Invasive Lobular Carcinoma of the Breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Fresia Pareja *Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3748-8049
Higinio Dopeso *Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0060-1861
Yi Kan Wang *Paige AI, New York, New York.ORCID 0009-0007-8467-203X
Andrea M GazzoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0009-9282-4667
David N BrownDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8249-3632
Monami BanerjeePaige AI, New York, New York.ORCID 0009-0004-8441-758X
Pier SelenicaDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0086-0513
Jan H BernhardPaige AI, New York, New York.ORCID 0009-0003-0381-355X
Fatemeh DerakhshanDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1346-589X
Edaise M da SilvaDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3281-7333
Lorraine Colon-CartagenaDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6863-9001
Thais BasiliDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3216-3544
Antonio MarraDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7310-7824
Jillian SuePaige AI, New York, New York.ORCID 0000-0002-7876-716X
Qiqi YeDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0005-5135-4292
Arnaud Da Cruz PaulaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7694-8760
Selma Yeni YildirimDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5925-561X
Xin PeiDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9961-6152
Anton SafonovDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4100-8071
Hunter GreenDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0002-3944-6803
Kaitlyn Y GillDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0004-7289-1145
Yingjie ZhuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1849-6019
Matthew C H LeePaige AI, New York, New York.ORCID 0000-0002-7167-4331
Ran A GodrichPaige AI, New York, New York.ORCID 0000-0003-3281-7253
Adam CassonPaige AI, New York, New York.ORCID 0000-0003-3186-1666
Britta WeigeltDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9927-1270
Nadeem RiazDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9873-5862
Hannah Y WenDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6794-5234
Edi BrogiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4737-8468
Diana L MandelkerDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4154-0567
Matthew G HannaDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7536-1746
Jeremy D KunzPaige AI, New York, New York.ORCID 0000-0001-5252-0145
Brandon RothrockPaige AI, New York, New York.ORCID 0000-0003-2237-6589
Sarat ChandarlapatyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4532-8053
Christopher KananDepartment of Computer Science, University of Rochester, Rochester, New York.ORCID 0000-0002-6412-995X
Joe OakleyPaige AI, New York, New York.ORCID 0000-0002-2345-9629
David S KlimstraPaige AI, New York, New York.ORCID 0000-0001-8814-1702
Thomas J FuchsPaige AI, New York, New York.ORCID 0000-0001-7603-8687
Jorge S Reis-FilhoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2969-3173

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Targeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3M
Breast Cancer Research Foundation (BCRF)Cycle for SurvivalNational Cancer Institute (NCI) P30CA008748National Cancer Institute (NCI) P50 CA247749 01NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749Starr Foundation (TSF)Susan G. Komen (SGK)
6 · The paper itself

Abstract

Artificial intelligence (AI) systems can improve cancer diagnosis, yet their development often relies on subjective histologic features as ground truth for training. Herein, we developed an AI model applied to histologic whole-slide images using CDH1 biallelic mutations, pathognomonic for invasive lobular carcinoma (ILC) in breast neoplasms, as ground truth. The model accurately predicted CDH1 biallelic mutations (accuracy = 0.95) and diagnosed ILC (accuracy = 0.96). A total of 74% of samples classified by the AI model as having CDH1 biallelic mutations but lacking these alterations displayed alternative CDH1 inactivating mechanisms, including a deleterious CDH1 fusion gene and noncoding CDH1 genetic alterations. Analysis of internal and external validation cohorts demonstrated 0.95 and 0.89 accuracy for ILC diagnosis, respectively. The latent features of the AI model correlated with human-explainable histopathologic features. Taken together, this study reports the construction of an AI algorithm trained using a genetic rather than histologic ground truth that can robustly classify ILCs and uncover CDH1 inactivating mechanisms, providing the basis for orthogonal ground truth utilization for development of diagnostic AI models applied to whole-slide image. Significance: Genetic alterations linked to strong genotypic-phenotypic correlations can be utilized to develop AI systems applied to pathology that facilitate cancer diagnosis and biologic discoveries.

Indexed as

Antigens, CDArtificial IntelligenceBreast NeoplasmsCadherinsCarcinoma, LobularGenomicsMutationAlgorithmsFemaleHumansAntigens, CDCadherinsCDH1 protein, human

Identifiers

PMID39106449
PMCPMC11479818

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.